A new non-steroidal ointment, meant to treat mild to moderate eczema in adults and children 2 years of age and older, is now available by doctor’s prescription in the United States.
The pharmaceutical company Pfizer received the FDA’s permission to market Eucrisa (crisaborole) in December.
“The approval of Eucrisa is great news for the children and adults suffering from mild to moderate eczema, a community that has not had a new prescription treatment for more than 10 years,” said Albert Bourla, group president of Pfizer Innovative Health.
Researchers examined both the safety and effectiveness of the ointment in two placebo-controlled trials with a total of 1,522 participants where they had them apply the anti-inflammatory lotion twice a day.
The data gathered by researchers showed that Eucrisa was an effective treatment in most patients. In just under a month, about 50 per cent of trial participants using the ointment reported that their eczema had cleared.
While side effects were infrequent in the studies, researchers say that a serious side effect of Eucrisa included “hypersensitivity reaction.” They recommend that patients who have a reaction to the drug’s active ingredient, crisaborole, should not use it.
More on this and other eczema drug treatments in the Spring 2017 edition of Allergic Living.